API in pharmaceuticals stands for Active Pharmaceutical Ingredient. It refers to the biologically active component of a drug that produces the intended therapeutic effects. APIs are the primary substances responsible for the drug's action, whether it is to treat, cure, prevent, or diagnose a disease. In pharmaceutical manufacturing, APIs are often synthesized or extracted and then formulated with other inactive substances, known as excipients, to create the final drug product. The API's purity, potency, and quality are critical for ensuring the safety and efficacy of the medication.
- nom del producte
- CAS No.
-
28523-86-6 -
26675-46-7 -
71-00-1 -
119615-63-3 -
658-79-7 -
64887-14-5 -
4857-44-7 -
51828-93-4 -
51828-94-5 -
51828-95-6 -
66872-75-1 -
3230-94-2 -
13115-71-4
What Are The Active Pharmaceutical Ingredients Called?
Active Pharmaceutical Ingredients are often simply referred to as "active ingredients". These ingredients are the core elements of pharmaceutical products that interact with biological systems to achieve the desired health outcomes. They are the substances that directly impact the treatment of conditions and are distinguished from inactive ingredients, which serve as carriers or enhancers but do not contribute to the drug's therapeutic effects.
Llegiu les nostres últimes notícies
Jan.15,2026
Practical Uses of 6-Amino-1,3-Dimethyluracil
Industries that adopt 6 amino 1 3 dimethyluracil benefit from consistent performance and reliable results. Our company is a leading manufacturer of 6 amino 1 3 dimethyluracil with cas no 6642 31 5 and formal EU-REACH registration. This ensures that each batch meets stringent quality standards
Llegeix més
Jan.15,2026
6-Amino-1,3-dimethyluracil in Pharmaceutical Intermediates
6-Amino-1,3-dimethyluracil is a critical intermediate in pharmaceutical manufacturing. It plays a central role in producing caffeine, theophylline, and aminophylline, compounds widely used in treatments for respiratory, neurological, and cardiovascular conditions. By incorporating 6-Amino-1
Llegeix més
